DNLI Share Price Performance
US$24.83
10.87 (77.87%)
40.9% undervalued intrinsic discount
US$42.00
Fair Value
Price US$24.83
AnalystHighTarget US$42.00
Fair ValueUS$42.00
Share Pricen/a
New Narrative • Aug 07
Denali Therapeutics Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
DNLI Community Narratives
AN
Fair Value
·Fair Value US$42 40.9% undervalued intrinsic discount
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
Denali Therapeutics is betting on a way to get medicines into the brain, starting with an early rare-disease launch and a pipeline that could reuse the same delivery platform across several conditions. The upside hinges on whether patients adopt the first therapy and whether upcoming trial results prove the approach works more broadly—or expose safety, competition, or approval hurdles.Read more
AN
US$42
40.9% undervalued intrinsic discount
Fair Value
Profit Margin
4.44%
Future PE
183.82x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
Fair Value: US$42 40.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Denali Therapeutics Inc. Key Details
About DNLI
- Founded
- 2013
- Employees
- 507
- CEO
- WebsiteView website
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
